nach oben

Metabolic Brain Disease

Erschienen in:

01.06.2013 | Original Paper

Disaccharides in the treatment of hepatic encephalopathy

verfasst von: Praveen Sharma, Barjesh Chander Sharma

Erschienen in: Metabolic Brain Disease | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Management of hepatic encephalopathy (HE) primarily involves avoidance of precipitating factors and administration of various ammonia-lowering therapies such as nonabsorbable disaccharides and antimicrobial agents like rifaximin. The nonabsorbable disaccharides which include lactulose and lactitol are considered the first-line therapy for the treatment of HE and minimal hepatic encephalopathy (MHE). Lactulose significantly improves cognitive function and health-related quality of life in patients with MHE. Lactitol is comparable to lactulose in the treatment of HE with fewer side effects. Lactulose has also shown to be effective in primary and secondary prophylaxis of HE. Disaccharides were found to be comparable to rifaximin in recent systemic reviews in the treatment of HE however conclusion was based on inclusion of some poor quality trials. Combination therapy of disaccharides either with rifaximin, L-ornithine L-aspartate,probiotics for the treatment of HE needs further validation in large studies.

Agrawal A, Sharma BC, Sharma P, Sarin SK (2012) Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy. Am J Gastroenterol 107(7):1043–1050PubMedCrossRef

Albrecht J, Zielińska M, Norenberg MD (2010) Glutamine as a mediator of ammonia neurotoxicity: a critical appraisal. Biochem Pharmacol 80(9):1303–1308PubMedCrossRef

Als-Nielsen B, Koretz RL, Kjaergard LL, Gluud C (2003) Branched-chain amino acids for hepatic encephalopathy Cochrane Database Syst Rev;(2):CD001939

Als-Nielsen B, Gluud LL, Gluud C (2004) Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ 328(7447):1046PubMedCrossRef

Atterbury CE, Maddrey WC, Conn HO (1978) Neomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy. A controlled, double-blind clinical trial. Am J Dig Dis 23:398–406PubMedCrossRef

Bajaj JS, Hafeezullah M, Hoffmann RG, Saeian K (2007) Minimal hepatic encephalopathy: a vehicle for accidents and traffic violations. Am J Gastroenterol 102:1903–1909PubMedCrossRef

Bajaj JS, Saeian K, Schubert CM, Hafeezullah M, Franco J, Varma RR, Gibson DP, Hoffmann RG, Stravitz RT, Heuman DM, Sterling RK, Shiffman M, Topaz A, Boyett S, Bell D, Sanyal AJ (2009a) Minimal hepatic encephalopathy is associated with motor vehicle. Hepatology 50(4):1175–1183PubMedCrossRef

Bajaj JS, Wade JB, Sanyal AJ (2009b) Spectrum of neurocognitive impairment in cirrhosis: implications for the assessment of hepatic encephalopathy. Hepatology 50(6):2014–2021PubMedCrossRef

Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, Sigal S, Sheikh MY, Beavers K, Frederick T, Teperman L, Hillebrand D, Huang S, Merchant K, Shaw A, Bortey E, Forbes WP (2010) Rifaximin treatment in hepatic encephalopathy. N Engl J Med 362(12):1071–1081PubMedCrossRef

Bismuth M, Funakoshi N, Cadranel JF, Blanc P (2011) Hepatic encephalopathy: from pathophysiology to therapeutic management. Eur J Gastroenterol Hepatol 23(1):8–22PubMedCrossRef

Blanc P, Daures JP, Rouillon JM, Peray P, Pierrugues R, Larrey D, Gremy F, Michel H (1992) Lactitol or lactulose in the treatment of chronic hepatic encephalopathy: results of a meta-analysis. Hepatology 15(2):222–228PubMedCrossRef

Blanc P, Couderc M, Peray P, Liautard J, Larrey D, Michel H (1993) Lactitol versus vancomycin in the treatment of acute hepatic encephalopathy: a double blind, randomized trial [abstract]. Gut 34:46CrossRef

Blei AT, Cordoba J (2001) Hepatic encephalopathy. Am J Gastroenterol 96:1968–1976PubMedCrossRef

Cammà C, Fiorello F, Tinè F, Marchesini G, Fabbri A, Pagliaro L (1993) Lactitol in treatment of chronic hepatic encephalopathy. A meta-analysis. Dig Dis Sci 38(5):916–922PubMedCrossRef

Clausen MR, Mortensen PB (1997) Lactulose, disaccharides and colonic flora: clinical consequences. Drugs 53(6):930–942PubMedCrossRef

Conn HO, Leevy CM, Vlacevic ZR, Rodgers JB, Maddrey WC, Seef L (1977) Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial. Gastroenterology 72:573–583PubMed

Cordóba J, Blei AT (1997) Treatment of hepatic encephalopathy. Am J Gastroenterol 92(9):1429–1439PubMed

Dhiman RK, Sawhney MS, Chawla YK, Dhiman RK, Sawhney MS, Chawla YK (2000) Efficacy of lactulose in cirrhotic patients with subclinical hepatic encephalopathy. Dig Dis Sci 45(8):1549–1552PubMedCrossRef

Dhiman RK, Saraswat VA, Sharma BK, Sarin SK, Chawla YK, Butterworth R, Duseja A, Aggarwal R, Amarapurkar D, Sharma P, Madan K, Shah S, Seth AK, Gupta RK, Koshy A, Rai RR, Dilawari JB, Mishra SP, Acharya SK (2010) Indian National Association for Study of the Liver. Minimal hepatic encephalopathy: consensus statement of a working party of the Indian National Association for Study of the Liver. J Gastroenterol Hepatol 25(6):1029–1041PubMedCrossRef

Eltawil KM, Laryea M, Peltekian K, Molinari M (2012) Rifaximin vs. conventional oral therapy for hepatic encephalopathy: a meta-analysis. World J Gastroenterol 18(8):767–777PubMedCrossRef

Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT (2002) Hepatic encephalopathy– definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 35:716–721PubMedCrossRef

Festi D, Mazzella G, Orsini M (1993) Rifaximin in the treatment of chronic hepatic encephalopathy: results of a multicenter study of efficacy and safety. Curr Ther Res 54(5):598–609CrossRef

Grandi M, Sacchetti C, Pederzoli S, Celani MF (1991) A clinical comparative study of crystalline pure lactulose and powder pure lactitol in portasystemic encephalopathy of cirrhotic patients. Minerva Gastroenterol Dietol 37(4):225–230PubMed

Groeneweg M, Quero JC, De Bruijn I, Hartmann IJC, Essink-bot MI, Hop WCJ, Schalm SW (1998) Subclinical hepatic encephalopathy impairs daily functioning. Hepatology 28:45–49PubMedCrossRef

Haüssinger D, Kircheis G, Fischer R, Schliess F, vom Dahl S (2000) Hepatic encephalopathy in chronic liver desease: a clinical manifestation of astrocyte swelling and low grade cerebral edema. J Hepatol 32:1035–1038PubMedCrossRef

Heredia D, Terés J, Orteu N, Rodés J (1988) Lactitol vs. lactulose in the treatment of chronic recurrent portal−systemic encephalopathy. J Hepatol 7(1):106–110PubMedCrossRef

Horsmans Y, Solbreux PM, Daenens C, Desager JP, Geubel AP (1997) Lactulose improves psychometric testing in cirrhotic patients with subclinical encephalopathy. Aliment Pharmacol Ther 11(1):165–170PubMedCrossRef

Jain L, Sharma BC, Sarin SK (2012) Serum endotoxin, inflammatory mediators and magnetic resonance spectroscopy before and after treatment in patients with minimal hepatic encephalopathy. J Gastroenterol Hepatol 27(suppl 5):216

Jiang Q, Jiang XH, Zheng MH, Jiang LM, Chen YP, Wang L (2008) Rifaximin versus nonabsorbable disaccharides in the management of hepatic encephalopathy: a meta−analysis. Eur J Gastroenterol Hepatol 20(11):1064–1070PubMedCrossRef

Lanthier PL, Morgan MY (1985) Lactitol in the treatment of chronic hepatic encephalopathy: an open comparison with lactulose. Gut 26:415–420PubMedCrossRef

Leevy CB, Phillips JA (2007) Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy. Dig Dis Sci 52:737–741PubMedCrossRef

Lockwood A, Yap E, Wong W (1991) Cerebral ammonia metabolism in patients with severe liver disease and minimal hepatic encephalopathy. J Cereb Blood Flow Metab 11:337–341PubMedCrossRef

Loguercio C, Del Vecchio BC, Coltorti M (1987) Enterococcus lactic acid bacteria strain SF68 and lactulose in hepatic encephalopathy: a controlled study. J Int Med Res 15(6):335–343PubMed

Loguercio C, Abbiati R, Rinaldi M, Romano A, Del Vecchio BC, Coltorti M (1995) Long-term effects of Enterococcus faecium SF68 versus lactulose in the treatment of patients with cirrhosis and grade 1-2 hepatic encephalopathy. J Hepatol 23(1):39–46PubMedCrossRef

Lunia MK, Sharma P, Sharma BC, Sarin SK (2012) A double blind randomised controlled trial comparing rifaximin plus lactulose with lactulose alone for treatment of hepatic encephalopathy. J Gastroenterol Hepatol 27(suppl 5):52

Luo M, Li L, Lu CZ, Cao WK (2011) Clinical efficacy and safety of lactulose for minimal hepatic encephalopathy: a meta-analysis. Eur J Gastroenterol Hepatol 23(12):1250–1257PubMedCrossRef

Mas A, Rodes J, Sunyer L, Rodrigo L, Planas R, Vargas V (2003a) Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol 38:51–58PubMedCrossRef

Mas A, Rodés J, Sunyer L, Rodrigo L, Planas R, Vargas V, Castells L, Rodríguez-Martínez D, Fernández-Rodríguez C, Coll I, Pardo A, Spanish Association for the Study of the Liver Hepatic Encephalopathy Cooperative Group (2003b) J Hepatol 38(1):51–58PubMedCrossRef

Massa P, Vallerino E, Dodero M (1993) Treatment of hepatic encephalopathy with rifaximin: double blind, double dummy study versus lactulose. Eur J Clin Res 4:7–18

McGee RG, Bakens A, Wiley K, Riordan SM, Webster AC (2011) Probiotics for patients with hepatic encephalopathy. Cochrane Database Syst Rev 9(11):CD008716

Mittal VV, Sharma BC, Sharma P, Sarin SK (2011) A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy. Eur J Gastroenterol Hepatol 23(8):725–732PubMedCrossRef

Mohammad RA, Regal RE, Alaniz C (2012) Combination therapy for the treatment and prevention of hepatic encephalopathy. Ann Pharmacother 46(11):1559–63PubMedCrossRef

Morgan MY, Hawley KE (1987) Lactitol vs. lactulose in the treatment of acute hepatic encephalopathy in cirrhotic patients: a double-blind, randomized trial. Hepatology 7(6):1278–1284PubMedCrossRef

Morgan MY, Alonso M, Stanger LC (1989) Lactitol and lactulose for the treatment of subclinical hepatic encephalopathy in cirrhotic patients. A randomised, cross-over study. J Hepatol 8(2):208–217PubMedCrossRef

Mullen K, Prakash R (2010) Rifaximin for the treatment of hepatic encephalopathy. Expert Rev Gastroenterol Hepatol 4(6):665–677PubMedCrossRef

Neff GW, Jones M, Broda T, Jonas M, Ravi R, Novick D, Kaiser TE, Kemmer N (2012) Durability of rifaximin response in hepatic encephalopathy. J Clin Gastroenterol 46(2):168–171PubMedCrossRef

Orlandi F, Freddara U, Candelaresi MT, Morettini A, Corazza GR, Di Simone A (1981) Comparison between neomycin and lactulose in 173 patients with hepatic encephalopathy: a randomized clinical study. Dig Dis Sci 26:498–506PubMedCrossRef

Paik YH, Lee KS, Han KH, Song KH, Kim MH, Moon BS, Ahn SH, Lee SJ, Park HJ, Lee DK, Chon CY, Lee SI, Moon YM (2005) Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study. Yonsei Med J 46(3):399–407PubMedCrossRef

Prasad S, Dhiman RK, Duseja A, Chawla YK, Sharma A, Agarwal R (2007) Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology 45(3):549–559PubMedCrossRef

Riggio O, Balducci G, Ariosto F, Merli M, Pieche U, Pinto G, Tremiterra S, Ziparo V, Capocaccia L (1989) Lactitol in prevention of recurrent episodes of hepatic encephalopathy in cirrhotic patients with portal-systemic shunt. Dig Dis Sci 34(6):823–829PubMedCrossRef

Riggio O, Masini A, Efrati C, Nicolao F, Angeloni S, Salvatori FM, Bezzi M, Attili AF, Merli M (2005) Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study. J Hepatol 42:674–679PubMedCrossRef

Riordan SM, Williams R (1997) Treatment of hepatic encephalopathy. N Engl J Med 337:473–479PubMedCrossRef

Romero-Gomez M, Boza F, Garcia-Valdecasas MS, García E, Aguilar-Reina J (2001) Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy. Am J Gastroenterol 96:2718–2723PubMed

Sanyal A, Younossi ZM, Bass NM, Mullen KD, Poordad F, Brown RS, Vemuru RP, Mazen Jamal M, Huang S, Merchant K, Bortey E, Forbes WP (2011) Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy - a double-blind placebo-controlled study. Aliment Pharmacol Ther 34(8):853–61PubMedCrossRef

Sharma P, Sharma BC (2010) Rifaximin treatment in hepatic encephalopathy. N Engl J Med 362(25):2423–2424PubMedCrossRef

Sharma P, Sharma BC (2011) Profile of hepatic encephalopathy in children with cirrhosis and response to lactulose. Saudi J Gastroenterol 17(2):138–141PubMedCrossRef

Sharma P, Sharma BC (2012) Lactulose for minimal hepatic encephalopathy in patients with extrahepatic portal vein obstruction. Saudi J Gastroenterol 18(3):168–172PubMedCrossRef

Sharma P, Sharma BC, Puri V, Sarin SK (2008) An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy. Eur J Gastroenterol Hepatol 20(6):506–511PubMedCrossRef

Sharma P, Sharma BC, Sarin SK (2009a) Predictors of nonresponse to lactulose for minimal hepatic encephalopathy in patients with cirrhosis. Liver Int 29(9):1365–1371PubMedCrossRef

Sharma BC, Sharma P, Agrawal A, Sarin SK (2009b) Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo. Gastroenterology 137:885–891PubMedCrossRef

Sharma P, Sharma BC, Sarin SK (2010) Predictors of nonresponse to lactulose in patients with cirrhosis and hepatic encephalopathy. Eur J Gastroenterol Hepatol 22(5):526–531PubMedCrossRef

Sharma P, Agrawal A, Sharma BC, Sarin SK (2011) Prophylaxis of hepatic encephalopathy in acute variceal bleed: a randomized controlled trial of lactulose versus no lactulose. J Gastroenterol Hepatol 26(6):996–1003PubMedCrossRef

Sharma P, Agrawal A, Sharma BC, Sarin SK (2012) Primary prophylaxis of hepatic encephalopathy in patients with cirrhosis: an open labeled randomized controlled trial of lactulose versus no lactulose. J Gastroenterol Hepatol 27(8):1329–1335PubMedCrossRef

Sidhu SS, Goyal O, Mishra BP, Sood A, Chhina RS, Soni RK (2011) Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial). Am J Gastroenterol 106(2):307–316PubMedCrossRef

Simmons F, Goldstein H, Boyle JD (1970) A controlled clinical trial of lactulose in hepatic encephalopathy. Gastroenterology 59:827–832PubMed

Sushma S, Dasarathy S, Tandon RK, Jain S, Gupta S, Bhist MS (1992) Sodium benzoate in the treatment of acute hepatic encephalopathy: a double-blind randomized trial. Hepatology 16(1):138–144PubMedCrossRef

Uribe M, Campollo O, Vargas F, Ravelli GP, Mundo F, Zapata L (1987) Acidifying enemas (lactitol and lactose) vs. nonacidifying enemas (tap water) to treat acute portal-systemic encephalopathy: a double-blind, randomized clinical trial. Hepatology 7:639–643PubMedCrossRef

Watanabe A, Sakai T, Sato S, Imai F, Ohto M, Arakawa Y, Toda G, Kobayashi K, Muto Y, Tsujii T, Kawasaki H, Okita K, Tanikawa K, Fujiyama S, Shimada S (1997) Clinical efficacy of lactulose in cirrhotic patients with and without subclinical hepatic encephalopathy. Hepatology 26(6):1410–1414PubMedCrossRef

Titel: Disaccharides in the treatment of hepatic encephalopathy
verfasst von: Praveen Sharma
Barjesh Chander Sharma
Publikationsdatum: 01.06.2013
Verlag: Springer US
Erschienen in: Metabolic Brain Disease / Ausgabe 2/2013
Print ISSN: 0885-7490
Elektronische ISSN: 1573-7365
DOI: https://doi.org/10.1007/s11011-013-9392-4

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2013

Correlation between degree and quality of sleep disturbance and the level of neuropsychiatric impairment in patients with liver cirrhosis

Encephalopathy and liver transplantation

Hepatic encephalopathy: an enigma from patient to enzyme and back

In vivo studies of brain metabolism in animal models of Hepatic Encephalopathy using 1H Magnetic Resonance Spectroscopy

Neurological complications post-liver transplantation: impact of nutritional status